PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
CMB International Global Markets  Equity Research  Company Update
Goertek (002241 CH)
3Q23 weakness in line Margin recovery on track into
4QFY24E  in-lin e  i n
Goerteks 3Q23 revenuenet profit growth of -6%-73% YoY (37%49% QoQ)
was largely in line with previous market expectations Impressive QoQ revenue
growth was driven by Meta Quest 3 and new smartphone launches in 3Q23 and
GPM improved 25ppts QoQ to 102% given higher utilization and new product
ramp-up Looking into 2H23E we expect margin recovery to continue with better
utilization and product mix and revenue will sustain QoQ growth on PS5Quest
3 momentum In the longer term we believe Goertek is set to benefit from ARVR
opportunities and Watch share gains delivering 58%13% YoY EPS growth in
FY2425E To reflect 1H23 results and better margins we adjust FY232425E
EPS by -4%9%9% and raise TP to RMB192 based on the same 25x FY24E
PE (7-yr hist avg) Maintain BUY
 3Q23 weakness expected GPM recovery to accelerate in 3Q23 3Q
salesnet profit declined 6%73% YoY and increased 37%49% QoQ largely
in line and 3Q GPM improved QoQ to 102% (vs 77%70% in 2Q1Q23)
boosted by improving product mix and better utilization on new product ramp-
up (Quest 3 PS5) We expect GPM to continue to recover to 102%105%
in FY2425E (vs 84% in FY23E) given improving utilization and favourable
product mix in FY2425E
 Acquisition of UPhoton to strengthen optics product portfolio Goertek
announced its plan to acquire 100% of Uphoton by cash and share issuance
Uphoton is specialized in micro-nano optics (DOE MLA) 3D structured light
module lighting visionlaser module and 3D sensing system solutions We
believe the acquisition will strengthen Goerteks vertical integration capability
700mn share buyback plan for the employee share option incentive scheme
highlighting its confidence in long-term business outlook
 202425 outlook PS5Quest 3 TWS recovery and XRgaming consoles
Riding on shipment momentum of PS5 Quest 3 we believe Goerteks VRAR
64% of FY2425E sales) backed by new product launches and share gains
in Meta Pico and Sony supply chains In the longer term we believe Goertek
is well-positioned to capture opportunities as a fully-integrated manufacturer
in the global ARVRXR industry
 Maintain BUY We think Goerteks 3Q results reflected better-than-feared
earnings recovery and Goerteks industry leadership and product roadmap
in TWSXRacousticsgaming segments will allow it to benefit from industry
MetaPico XR products and continued margin recovery
(Previous TP
UpDownside
Mkt Cap (RMB mn)
Avg 3 mths to (RMB mn)
52w HighLow (RMB)
Total Issued Shares (mn)
Source FactSet
Shareholding Structure
Source Bloomberg
Source FactSet
12-mth Price Performance
Source FactSet
Related reports
1 Goertek (002241 CH)-1H23
weakness in-line Lower TP
on slower demand recovery-
30 Aug 2023 (link)
(YE 31 Dec)
Revenue (RMB mn)
YoY growth (%)
Net profit (RMB mn)
EPS (Reported) (RMB)
YoY growth (%)
Consensus EPS (RMB)
Source Company data Bloomberg CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
3Q23 results review
Figure 1 3Q23 review
Source Company data CMBIGM estimates
Figure 2 Earnings revision
Source CMBIGM estimates
Figure 3 CMBIGM estimates vs consensus
Source Bloomberg CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Figure 4 Revenue breakdown
Speakerreceiver
MIC (ECMMEMS)
ARVR Headset
RoboticsUAVsmart light
Non-main business
Source Company data CMBIGM estimates
Figure 5 PL forecast
Source Company data CMBIGM estimates
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Maintain BUY with new TP of RMB1922
Our new TP of RMB1922 is based on the same 25x FY24E PE (7-year hist avg) Overall
we believe Goerteks industry leadership and product roadmap in TWSXR
MetaPico XR products and margin recovery
Figure 6 Peers valuation
Source Bloomberg CMBIGM estimates TP under review
Figure 7 12M forward PE band
Source Bloomberg CMBIGM
Figure 8 12M forward PB band
Source Bloomberg CMBIGM
1-yr Forward PE
1-yr Forward PE
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
RD expense
Investment gainloss
Other gains(losses)
Pre-tax profit
YE 31 Dec (RMB mn)
Cash  equivalents
Financial assets at FVTPL
Non-current assets
Investment in JVs  assos
Financial assets at FVTPL
Other non-current assets
Short-term borrowings
Other current liabilities
Non-current liabilities
Long-term borrowings
Other non-current liabilities
Total shareholders equity
Total equity and liabilities
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
YE 31 Dec (RMB mn)
Profit before taxation
Depreciation  amortization
Change in working capital
Net cash from operations
Acquisition of subsidiaries investments
Net proceeds from disposal of short-term
Net cash from investing
Proceeds from share issues
Net cash from financing
Cash at the beginning of the year
Cash at the end of the year
Return on equity (ROE)
GEARINGLIQUIDITYACTIVITIES
Current ratio (x)
Receivable turnover days
Inventory turnover days
Payable turnover days
Div yield (%)
Source Company data CMBIGM estimates Note The calculation of net cash includes financial assets
PLEASE READ THE ANALYST CERTIFICATION AND IMPORTANT DISCLOSURES ON LAST PAGE
Disclosures  Disclaimers
Analyst Certification
The research analyst who is primary responsible for the content of this research report in whole or in part certifies that with respect to the securities
or issuer that the analyst covered in this report (1) all of the views expressed accurately reflect his or her personal views about the subject securities
this report
Besides the analyst confirms that neither the analyst nor hisher associates (as defined in the code of conduct issued by The Hong Kong Securities
and Futures Commission) (1) have dealt in or traded in the stock(s) covered in this research report within 30 calendar days prior to the date of issue
of this report (2) will deal in or trade in the stock(s) covered in this research report 3 business days after the date of issue of this report (3) serve as
covered in this report
 Stock with potential return of over 15% over next 12 months
 Stock with potential return of 15% to -10% over next 12 months
 Stock with potential loss of over 10% over next 12 months
 Stock is not rated by CMBIGM
OUTPERFORM                     Industry expected to outperform the relevant broad market benchmark over next 12 months
MARKET-PERFORM             Industry expected to perform in-line with the relevant broad market benchmark over next 12 months
UNDERPERFORM                 Industry expected to underperform the relevant broad market benchmark over next 12 months
CMB International Global Markets Limited
Address 45F Champion Tower 3 Garden Road Hong Kong Tel (852) 3900 0888   Fax (852) 3900 0800
CMB International Global Markets Limited (CMBIGM) is a wholly owned subsidiary of CMB International Capital Corporation Limited (a wholly owned
subsidiary of China Merchants Bank)
Important Disclosures
There are risks involved in transacting in any securities  The information contained in this report may not be suitable for the purposes of all investors  CMBIGM
does not provide individually tailored investment advice This report has been prepared without regard to the individual investment objectives financial position
or special requirements  Past performance has no indication of future performance and actual events may differ materially from that which is contained in the
report  The value of and returns from any investments are uncertain and are not guaranteed and may fluctuate as a result of their dependence on the
and strategies and encourages investors to consult with a professional financial advisor in order to make their own investment decisions
This report or any information contained herein have been prepared by the CMBIGM solely for the purpose of supplying information to the clients of CMBIGM
or its affiliate(s) to whom it is distributed  This report is not and should not be construed as an offer or solicitation to buy or sell any security or any interest in
securities or enter into any transaction  Neither CMBIGM nor any of its affiliates shareholders agents consultants directors officers or employees shall be
liable for any loss damage or expense whatsoever whether direct or consequential incurred in relying on the inform ation contained in this report  Anyone
making use of the information contained in this report does so entirely at their own risk
The information and contents contained in this report are based on the analyses and interpretations of information believed to be publicly available and reliable
the information advices and forecasts on an AS IS basis  The information and contents are subject to change without notice CMBIGM may issue other
publications having information and or conclusions different from this report  These publications reflect different assumption point-of-view and analytical
this report
on behalf of its clients from time to time Investors should assume that CMBIGM does or seeks to have investment banking or other business relationships with
and CMBIGM will not assume any responsibility in respect thereof This report is for the use of intended recipients only and this publication may not be
reproduced reprinted sold redistributed or published in whole or in part for any purpose without prior written consent of CMBIGM
For recipients of this document in the United Kingdom
This report has been provided only to persons (I)falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005
(as amended from time to time)(The Order) or (II) are persons falling within Article 49(2) (a) to (d) (High Net Worth Companies Unincorporated Associations
etc) of the Order and may not be provided to any other person without the prior written consent of CMBIGM
For recipients of this document in the United States
CMBIGM is not a registered broker-dealer in the United States  As a result CMBIGM is not subject to US rules regarding the preparation of research reports
and the independence of research analysts  The research analyst who is primary responsible for the content of this research report is not registered or qualified
as a research analyst with the Financial Industry Regulatory Authority (FINRA)  The analyst is not subject to applicable restrictions under FINRA Rules
intended to ensure that the analyst is not affected by potential conflicts of interest that could bear upon the reliability of the research report This report is
intended for distribution in the United States solely to major US institutional investors as defined in Rule 15a-6 under the US Securities Exchange Act of
1934 as amended and may not be furnished to any other person in the United States Each major US institutional investor that receives a copy of this report
by its acceptance hereof represents and agrees that it shall not distribute or provide this report to any other person Any US recipient of this report wishing to
effect any transaction to buy or sell securities based on the information provided in this report should do so only through a US-registered broker-dealer
For recipients of this document in Singapore
This report is distributed in Singapore by CMBI (Singapore) Pte Limited (CMBISG) (Company Regn No 201731928D) an Exempt Financial Adviser as defined
in the Financial Advisers Act (Cap 110) of Singapore and regulated by the Monetary Authority of Singapore CMBISG may distribute reports produced by its
respective foreign entities affiliates or other foreign research houses pursuant to an arrangement under Regulation 32C of the Financial Advisers Regulations
Where the report is distributed in Singapore to a person who is not an Accredited Investor Expert Investor or an Institutional Investor as defined in the Securities
and Futures Act (Cap 289) of Singapore CMBISG accepts legal responsibility for the contents of the report to such persons only to the extent required by law
Singapore recipients should contact CMBISG at 65 6350 4400 for matters arising from or in connection with the report